Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Imaging The Heart In The Cancer Patient
J. Fox, H. Strauss
Published 2013 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
The average age of a cancer patient is 67. Sexagenarians with cancer are likely to have comorbidities at the time of diagnosis. Cancer patients > 55 years old have an average of ∼ 2.9 comorbidities, while cancer patients older than 75 have an average of 4.2 comorbidities. The likelihood of coronary artery disease as an etiology of this comorbidity increases with the age of the patient. Cardiovascular comorbidity is present in ∼ 20% of patients with neoplasm. These comorbidities increase the risk of a serious cardiovascular event during treatment. An additional risk factor is limited work capacity. If patients cannot perform 4 METS of work, their all cause mortality is increased. Patients with cancer and known cardiovascular comorbidity or risk factors such as diabetes, hypertension, smoking history, or limited work capacity should have medical clearance prior to invasive diagnostic procedures, major surgery, mediastinal radiation, and/or potentially cardiotoxic chemotherapy. Medical clearance should include a detailed cardiovascular history and physical examination. This information will permit calculation of a clinical score (such as POSSUM) to define the risk of adverse events as a result of a major surgical procedure, blood tests to determine hematologic and renal status, and if necessary, assessment of the patients work capacity. Stress testing with imaging should be done in patients with an intermediate risk of coronary heart disease and considered in patients with limited work capacity or advanced age. In selected patients, coronary CT angiography or coronary calcium score may be a suitable evaluation. In patients with cancer of the esophagus, breast, lung, melanoma, or lymphoma, chest-CT and PET/CT studies should be carefully evaluated to detect possible pericardial or myocardial involvement.
This paper references
Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort
D. Mulrooney (2009)
Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.
D. Cardinale (2010)
Increased FDG uptake in the wall of the right atrium in people who participated in a cancer screening program with whole-body PET
H. Fujii (1999)
Adriamycin (14-hydroxydaunomycin), a novel antitumor antibiotic.
F. Arcamone (1969)
The rising incidence of second cancers: patterns of occurrence and identification of risk factors for children and adults.
L. Morton (2014)
High incidence of adriamycin cardiotoxicity in children even at low cumulative doses: role of radionuclide cardiac angiography.
S. Agarwala (2000)
Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
M. Ewer (2005)
Therapy Insight: malignant primary cardiac tumors
M. Reardon (2006)
Incidence and Significance of Myocardial Injury After Surgical Treatment of Head and Neck Cancer
S. A. Nouraei (2007)
First, Do no Harm
F. Lynce (2008)
Comparison of risk stratification with pharmacologic and exercise stress myocardial perfusion imaging: A meta-analysis
S. M. Navare (2004)
Comparative values of gated blood-pool SPECT and CMR for ejection fraction and volume estimation
L. Sibille (2011)
D. Keefe (2002)
Assessment of cardiac function by three-dimensional echocardiography compared with conventional noninvasive methods.
A. Gopal (1995)
A scintiphotographic method for measuring left ventricular ejection fraction in man without cardiac catheterization.
H. Strauss (1971)
Serum HER2 levels are increased in patients with chronic heart failure
Patrick J. Perik (2007)
Left ventricular ejection fraction: are the revised cut-off points for defining systolic dysfunction sufficiently evidence based?
G. Mahadevan (2008)
Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group.
L. Steinherz (1992)
Cardiac history and risk of post-cystectomy cardiac complications.
M. Fisher (2009)
111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.
M. A. de Korte (2007)
Images in cardiovascular medicine. Diffuse infiltration of lymphoma of the myocardium mimicking clinical hypertrophic cardiomyopathy.
P. Lee (2006)
Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.
S. Lipshultz (1991)
Obtention d'amines primaires par action d'organo-magnesiens sur l'acetoxime
G. Alvernhe (1972)
Perioperative myocardial ischemia in patients undergoing noncardiac surgery--I: Incidence and severity during the 4 day perioperative period. The Study of Perioperative Ischemia (SPI) Research Group.
D. Mangano (1991)
Heart and tumors: location, metastasis, clinical manifestations, diagnostic approaches and therapeutic considerations
K. Ekmektzoglou (2008)
A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin.
M. Ewer (1984)
Influence of preoperative exercise capacity on length of stay after thoracic cancer surgery.
H. Weinstein (2007)
Cardiovascular problems in noncardiac surgery
M. London (2009)
Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.
E. Perez (2008)
99mTc-Pyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis From the Transthyretin-Related Familial and Senile Cardiac Amyloidoses
S. Bokhari (2013)
2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery.
L. Fleisher (2009)
2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
L. Fleisher (2014)
Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia
C. Tan (1967)
The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology.
L. Cooper (2007)
Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.
D. Cardinale (2010)
Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography.
J. Gottdiener (1981)
Do no harm.
A. Jonsen (1978)
Intermittent FDG Uptake in Lipomatous Hypertrophy of the Interatrial Septum on Serial PET/CT Scans
P. Gerard (2008)
Subcellular effects of adriamycin in the heart: a concise review.
P. Singal (1987)
An estimation of the global volume of surgery: a modelling strategy based on available data
T. Weiser (2008)
Cardiac risk stratification for noncardiac surgery: Update from the American College of Cardiology/American Heart Association 2007 guidelines
L. Fleisher (2009)
Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
D. Cardinale (2006)
Cardiac dysfunction in the trastuzumab clinical trials experience.
A. Seidman (2002)
Multiple gated cardiac blood pool imaging for left ventricular ejection fraction: validation of the technique and assessment of variability.
F. Wackers (1979)
Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?
N. Bellenger (2000)
Global Coronary Flow Reserve Is Associated With Adverse Cardiovascular Events Independently of Luminal Angiographic Severity and Modifies the Effect of Early Revascularization
V. R. Taqueti (2015)
A meta-analysis comparing the prognostic accuracy of six diagnostic tests for predicting perioperative cardiac risk in patients undergoing major vascular surgery
M. Kertai (2003)
Long-term cardiac safety of dose-dense anthracycline therapy cannot be predicted from early ejection fraction data.
M. Ewer (2009)
Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II.
K. M. Tewey (1984)
Perioperative Organ Injury
K. Bartels (2013)
Heart Disease and Stroke Statistics—2015 Update: A Report From the American Heart Association
D. Mozaffarian (2015)
Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy.
J. Mason (1978)
Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.
M. Procter (2010)
Cancer and comorbidity
K. Ogle (2000)
Histological analysis of coronary artery lesions in fatal postoperative myocardial infarction.
M. Cohen (1999)
Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy.
J. Isner (1983)
Metastatic involvement of the heart and pericardium: CT and MR imaging.
C. Chiles (2001)
Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury.
S. Lipshultz (1997)
Unusual Primary Tumors Of The Heart
T. Salm (2000)
Previous Coronary Stent Implantation and Cardiac Events in Patients Undergoing Noncardiac Surgery
N. Cruden (2010)
Primary cardiac tumors.
N. Silverman (1980)
Surveillance and prevention of major perioperative ischemic cardiac events in patients undergoing noncardiac surgery: a review
P. Devereaux (2005)
Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging.
J. Walker (2010)
The role of oxidative stress in the genesis of heart disease.
P. Singal (1998)
Comparison of radionuclide ventriculography using SPECT and planar techniques in different cardiac conditions
T. Massardo (2007)
Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice.
A. Riad (2009)
The Incidence of Awareness During Anesthesia: A Multicenter United States Study
P. Sebel (2004)
Trastuzumab--mechanism of action and use in clinical practice.
C. Hudis (2007)
Insights into cardiovascular side-effects of modern anticancer therapeutics
S. Stortecky (2010)
A clinicopathologic analysis of adriamycin cardiotoxicity
E. Lefrak (1973)
Pathology of fatal perioperative myocardial infarction: implications regarding pathophysiology and prevention.
M. M. Dawood (1996)
Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer.
M. Tukenova (2010)
Cardiac toxicity of daunorubicin.
G. Bonadonna (1969)
Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.
J. Alexander (1979)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
Synthesis and evaluation of 18F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter
Hanwen Zhang (2013)
An electronic application for rapidly calculating Charlson comorbidity score
W. Hall (2004)
Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery.
T. Lee (1999)
LOWERING CARDIAC RISK IN NONCARDIAC SURGERY
L. Fleisher (2001)
Analysis of Left Ventricular Function from Multiple Gated Acquisition Cardiac Blood Pool Imaging Comparison to Contrast Angiography
R. Burow (1977)
In Vivo Visualization of Amyloid Deposits in the Heart with 11C-PIB and PET
G. Antoni (2013)
Ischemia, revascularization, and perioperative troponin elevation after vascular surgery.
D. Mukherjee (2004)
Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy
F. Pein (2004)
Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.
V. Guarneri (2006)
The pathophysiology of perioperative myocardial infarction: facts and perspectives.
G. Landesberg (2003)
2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
L. Fleisher (2014)
Non-invasive cardiac stress testing before elective major non-cardiac surgery: population based cohort study
D. Wijeysundera (2010)
Myocardial perfusion imaging and cardiovascular outcomes in a cancer population.
Shalabh Chandra (2009)
Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
M. Pinder (2007)
Herceptin and the heart--a molecular modifier of cardiac failure.
K. Chien (2006)
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
M. Hensley (2009)
Imaging cardiac amyloidosis: a pilot study using 18F-florbetapir positron emission tomography
S. Dorbala (2014)
Correspondence of left ventricular ejection fraction determinations from two-dimensional echocardiography, radionuclide angiography and contrast cineangiography.
M. M. Naik (1995)
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
T. Suter (2007)
Congestive heart failure in patients treated with doxorubicin
S. Swain (2003)
Annual Report to the Nation on the status of cancer, 1975‐2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer
B. Edwards (2014)
Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.
M. Bristow (1981)
Does left ventricular diastolic function deteriorate earlier than left ventricular systolic function in anthracycline cardiotoxicity?
C. Patel (2010)
How to differentiate benign versus malignant cardiac and paracardiac 18F FDG uptake at oncologic PET/CT.
A. Maurer (2011)
Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach.
M. Janssen-Heijnen (2005)
Preoperative risk stratification using gated myocardial perfusion studies in patients with cancer.
K. Chang (2007)
Age-Specific Exercise Capacity Threshold for Mortality Risk Assessment in Male Veterans
P. Kokkinos (2014)
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.
R. G. Schwartz (1987)
99mTc-aprotinin scintigraphy in amyloidosis.
B. Schaadt (2003)
Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.
M. Ewer (2005)
Quantification of left ventricular volumes and ejection fraction from gated 99mTc-MIBI SPECT: MRI validation and comparison of the Emory Cardiac Tool Box with QGS and 4D-MSPECT.
W. Schaefer (2005)
Scintigraphic Techniques for Early Detection of Cancer Treatment–Induced Cardiotoxicity
L. de Geus-Oei (2011)
Cardiopulmonary exercise testing as a screening test for perioperative management of major surgery in the elderly.
P. Older (1999)
Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program.
M. Hayat (2007)
Real-time three-dimensional echocardiographic assessment of mitral valve: Is it really superior to 2D transesophageal echocardiography?
C. Mukherjee (2011)
Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment.
E. Harris (2006)
Myocardial metastasis or benign brown fat?
P. M. Rao (2009)
Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk
P. Devereaux (2005)
A modified method for the in vivo labeling of red blood cells with Tc-99m: concise communication.
R. Callahan (1982)
Perioperative cardiac evaluation, monitoring, and risk reduction strategies in noncardiac surgery patients
E. J. Bakker (2011)
Cardiac toxicity 4 to 20 years after completing anthracycline therapy.
L. Steinherz (1991)
Angiographic investigation of the pathophysiology of perioperative myocardial infarction
W. Duvall (2012)
Perioperative Cardiac Morbidity
D. Mangano (1990)
The radionuclide ejection fraction: a comparison of three radionuclide techniques with contrast angiography.
E. Folland (1977)
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
B. Kaufman (2009)
Myocardial infarction after vascular surgery: the role of prolonged stress-induced, ST depression-type ischemia.
G. Landesberg (2001)
Relation between Preoperative and Intraoperative New Wall Motion Abnormalities in Vascular Surgery Patients: A Transesophageal Echocardiographic Study
W. Galal (2010)
Risk factors for doxorubicin-induced congestive heart failure.
D. V. Von Hoff (1979)
Criteria for the accurate interpretation of changes in left ventricular ejection fraction and cardiac volumes as assessed by rest and exercise gated radionuclide angiography.
J. Mahmarian (1991)
This paper is referenced by
Enhanced Sensitivity to Low Dose Irradiation of ApoE−/− Mice Mediated by Early Pro-Inflammatory Profile and Delayed Activation of the TGFβ1 Cascade Involved in Fibrogenesis
V. Monceau (2013)
Cardiac Imaging in Clinical Trials
George P. Heyrich (2014)